A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy

NCT02177071 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

211

Enrollment

OTHER

Sponsor class

Conditions

Crohn's Disease

Interventions

DRUG: INFLIXIMAB
DRUG: AZATHIOPRINE
DRUG: MERCAPTOPURINE
DRUG: Methotrexate

Sponsor

Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

Collaborators

[object Object]